01—Abstract
Summary
Summary of the 10-K filed February 11, 2020. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported fiscal 2019 total revenue of $2.62 billiona, up from $2.27 billion in fiscal 2018, an increase the filing states as $355.1 million, or 15.7%.
Growth was driven mainly by the Discovery and Safety Assessment (DSA) segment, which generated $1.62 billionb of revenue, up 22.9%, helped by the Citoxlab and MPI Research acquisitions and by demand from biotechnology clients. Research Models and Services (RMS) revenue was $537.1 million, up 3.3%, and Manufacturing revenue was $465.1 million, up 8.3%. Operating income rose to $351.2 million from $331.4 million, though operating margin declined to 13.4% from 14.6%.
Net income attributable to common shareholders increased to $252.0 millionc, or $5.07 diluted EPS, helped by a $20.6 million deferred tax asset recognized for net operating losses expected to be used in the future. The balance sheet grew with acquisitions. Total debt and finance leases were $1.91 billion at year end, with the company funding the Citoxlab acquisition ($527.7 million) and issuing $500.0 million of 4.25% Senior Notes due 2028 in October 2019.
The revolving credit facility was increased to $2.05 billiond in November 2019. Subsequent to year end, in January 2020, the company acquired HemaCare Corporation for approximately $380 million in cash, funded through cash on hand and borrowings under the revolver. Cash flow from operations was $480.9 million in 2019, compared with $441.1 million in 2018.
The filing also discloses a March 2019 unauthorized access to certain information systems that copied client data, which the company states has been remediated, with a financial impact it describes as not material. The company reported $129.1 million remaining under its stock repurchase authorization and did not repurchase shares under the program in 2019. It stated it is not party to any legal proceedings that are material to its business.
02—Key points
Key Highlights
- Total revenue of $2,621.2 million in fiscal 2019, up $355.1 million or 15.7% from fiscal 2018, with the decline in foreign exchange reducing revenue by $36.1 million or 1.5%.
- DSA segment revenue rose 22.9% to $1,619.0 million, contributing 61.8% of total revenue, supported by the Citoxlab and MPI Research acquisitions and biotechnology client demand.
- Operating income of $351.2 million, up from $331.4 million, with operating margin of 13.4% compared with 14.6% in fiscal 2018.
- Net income attributable to common shareholders of $252.0 million, or $5.07 per diluted share, including a $20.6 million tax benefit from recognizing net operating loss deferred tax assets.
- Cash flow from operations of $480.9 million, and capital expenditures of $140.5 million.
- Total debt and finance leases of $1.91 billion at year end; issued $500.0 million of 4.25% Senior Notes due 2028 and expanded the revolving facility to $2.05 billion.
- Acquired HemaCare Corporation in January 2020 for approximately $380 million in cash, to be reported in the RMS segment.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 11, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $2.62B$2.27B | +15.7% |
| SG&A Expenses | $517.62M$443.85M | +16.6% |
| Operating Income | $351.15M$331.38M | +6.0% |
| Interest Expense | $60.88M$63.77M | −4.5% |
| Net Income | $252.02M$226.37M | +11.3% |
| EPS (Basic) | $5.17$4.72 | +9.5% |
| EPS (Diluted) | $5.07$4.62 | +9.7% |
| Shares Outstanding (Basic) | 48.73M47.95M | +1.6% |
| Shares Outstanding (Diluted) | 49.69M49.02M | +1.4% |
05—Questions
Frequently Asked Questions
What drove revenue growth in fiscal 2019?
The filing attributes the 15.7% revenue increase primarily to growth in the DSA and Manufacturing segments and to the acquisitions of Citoxlab and MPI Research. DSA revenue grew 22.9%, with Citoxlab contributing $123.7 million and MPI Research contributing $73.0 million of service revenue growth. Safety Assessment and Discovery Services also grew from biotechnology client demand and higher pricing.
Why did operating margin decline even though operating income increased?
The filing states that operating income rose $19.8 million, but operating margin fell to 13.4% from 14.6%. The company cites increased amortization expense and acquisition-related costs, restructuring costs, investments in personnel and facility expansions, and company-wide IT and infrastructure projects as factors that reduced margin, partly offset by improved volume, mix, pricing and productivity initiatives.
How did the company finance its acquisitions and what is its debt position?
The Citoxlab acquisition ($527.7 million) was funded with cash on hand and revolver borrowings. The company issued $500.0 million of 4.25% Senior Notes due 2028 in October 2019 and used the proceeds, along with available cash, to prepay $500.0 million of its term loan. As of December 28, 2019, total debt and finance leases were $1.91 billion, and the weighted average interest rate on debt was 3.46%. The company stated it was in compliance with all Credit Facility covenants.
What was the March 2019 information systems incident?
The filing states that in March 2019 the company detected evidence that an unauthorized third party accessed certain information systems and copied data, with the affected information including client information. The company reported completing remediation in December 2019 and said the financial impact of the event is not material. The filing also notes the company has added security safeguards such as multi-factor authentication and increased network monitoring.
What is the company's capital return policy?
The company has not declared or paid cash dividends and does not anticipate paying dividends in the foreseeable future. As of December 28, 2019, $129.1 million remained under its authorized stock repurchase program, and it made no open-market repurchases in fiscal 2019. Shares were acquired through netting for statutory tax withholding on equity awards, totaling $18.1 million in 2019.
06—Continue